



## Appendix A: Oral treatment duration Calculations

| Drug   | Indication   | Prescription length (days) | Treatment end |
|--|--|----------------------------|---------------|
| Abemaciclib (with fulvestrant)                 | Breast cancer  | 28                         | 90            |
| Crizotinib                                     | ROS1-positive advanced non-small-cell lung cancer    | 28                         | 90            |
| Ibrutinib                                      | Waldenstrom's macroglobulinemia                      | 28                         | 120           |
| Ixazomib (with lenalidomide and dexamethasone) | Multiple Myeloma                                     | 28                         | 90            |
| Larotrectinib                                  | NTRK fusion-positive solid tumours                   | 28                         | 90            |
| Niraparib                                      | Ovarian cancer after second response to chemotherapy | 28                         | 90            |
| Olaparib maintenance first line                | Ovarian, fallopian tube and peritoneal cancer        | 28                         | 90            |
| Olaparib (maintenance second line)             | Ovarian, fallopian tube and peritoneal cancer        | 28                         | 90            |
| Osimertinib                                    | EGFR and T790M mutation positive NSCLC               | 28                         | 90            |

| <b>Drug</b>  | <b>Indication</b>  | <b>Prescription length (days)</b>                                  | <b>Treatment end</b> |
|--|--|--|----------------------|
| Palbociclib in combination with fulvestrant <sup>1</sup> | Advanced, HR+ HER2- breast cancer after endocrine therapy  | 29 if within the first month of commencing treatment 28 thereafter | 90                   |
| Ribociclib (with fulvestrant)                            | Breast cancer  | 21   | 90                   |
| Rucaparib  | Ovarian, fallopian tube and peritoneal cancer  | 28   | 90                   |
| Venetoclax   | Chronic Lymphocytic Leukaemia  | 7 if within 35 days of commencing treatment 28 thereafter          | 90                   |
| Venetoclax (with obinutuzumab)                           | Chronic lymphocytic leukaemia for subgroup with del(17p)/TP53 mutation for whom FCR or BR are suitable | 28   | 90                   |

---

<sup>1</sup> While palbociclib has a 28-day cycle fulvestrant is administered in the first month on days 1, 15, 29, then once a month